Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 26, 2023
- Pharmaceuticals
- R&D
Galderma Announces Nemolizumab Data Published in the New England Journal of Medicine
TOKYO, October 26, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release regarding the results of a Phase III clinical study (OLYMPIA 2) for prurigo nodularis of nemolizumab published in the New England Journal of Medicine (NEJM). Nemolizumab is a humanized anti-human IL-31 receptor A monoclonal antibody, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in prurigo nodularis patients
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
